![]() |
Delaware | 36-3640402 | ||||
(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification Number) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Common Stock, par value $0.01 per share | SRCL | Nasdaq Global Select Market |
Page No. | ||||||||
2024 Q1 10-Q Report | Stericycle, Inc. ● | 3 |
Abbreviation | Description | ||||
2023 Form 10-K | Annual report on Form 10-K for the year ended December 31, 2023 | ||||
Adjusted Income from Operations | Income from Operations adjusted for certain items discussed in Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | ||||
AI | Artificial intelligence | ||||
Credit Agreement | Credit Agreement dated September 30, 2021, First Amendment dated April 26, 2022, and Second Amendment dated June 15, 2023, among the Company and certain subsidiaries as borrowers. Bank of America, N.A., as administrative agent, swing line lender, a lender and a letter of credit issuer and the other lenders party thereto, as amended | ||||
Credit Agreement Defined Debt Leverage Ratio | As of any date of determination, the ratio of (a) (i) Consolidated Funded Indebtedness as of such date minus (ii) Unrestricted Cash as of such date to (b) Consolidated EBITDA (each as defined in the Credit Agreement) for the period of four fiscal quarters most recently ended on or prior to such date | ||||
Credit Facility | The Company's $1.2 billion credit facility due in September of 2026 granted under the terms of the Credit Agreement | ||||
DEA | U.S. Drug Enforcement Administration. The DEA is a division of the DOJ. It is the federal agency which regulates the manufacture, dispensing, storage, and shipment of controlled substances including medications with human abuse potential | ||||
DOJ | U.S. Department of Justice | ||||
Domestic Environmental Solutions | Hazardous Waste Solutions and Manufacturing and Industrial Services (Divested April 2020) | ||||
DSO | Days Sales Outstanding as reported, defined as the average number of days that it takes a company to collect payment after revenue has been recorded, computed as the trailing twelve months of Revenues for the period ended, divided by the Accounts Receivable balance at the end of the period. Days Sales Outstanding, net of Deferred Revenues is similarly computed except Accounts Receivable balance is netted with Deferred Revenues. | ||||
DTSC | U.S. Department of Toxic Substances Control | ||||
EBITDA | Earnings Before Interest, Taxes, Depreciation & Amortization. Another common financial term utilized by Stericycle to analyze the core profitability of the business before interest, tax, depreciation and amortization | ||||
Enviri | Enviri Corporation, a Delaware Corporation, formerly known as Harsco Corporation | ||||
ERP | Enterprise Resource Planning | ||||
Exchange Act | U.S. Securities Exchange Act of 1934 | ||||
FASB | Financial Accounting Standards Board | ||||
FCPA | U.S. Foreign Corrupt Practices Act | ||||
FCPA Settlement | FCPA settlement with the SEC, the DOJ and Brazil authorities of approximately $90 million and engagement of an independent compliance monitor for 2 years and self-reporting for additional year | ||||
International | Operating segment including Belgium, France, Germany, Ireland, Luxembourg, Portugal, Spain, and U.K. The following countries were divested in 2023: Australia, Brazil, Republic of Korea, Romania, Singapore, and United Arab Emirates | ||||
IRS | U.S. Internal Revenue Service | ||||
LIBOR | London Interbank Offered Rate - benchmark interest rate that was replaced by SOFR | ||||
Net Debt | As defined in the Credit Agreement, adding back unamortized debt issuance costs, less cash and cash equivalents | ||||
North America | Operating segment including U.S., Canada and Puerto Rico | ||||
NOV | Notice of Violation | ||||
Other Costs | Represents corporate enabling and shared services costs, annual incentive and stock-based compensation | ||||
Purchase Agreement | Stock Purchase Agreement, dated as of February 6, 2020, by and between Stericycle, Inc., and the Harsco Corporation (now known as Enviri) and CEI Holding LLC, a Delaware limited liability company and subsidiary of Harsco Corporation (now known as Enviri) | ||||
PSU | Performance-based Restricted Stock Unit | ||||
RSU | Restricted Stock Unit | ||||
RWCS | Regulated Waste and Compliance Services, a business unit that provides regulated medical waste services | ||||
SEC | U.S. Securities and Exchange Commission | ||||
Senior Notes | 5.375% ($600.0 million) Senior Notes due July 2024 and 3.875% ($500.0 million) Senior Notes due January 2029. July 2024 Senior Notes were redeemed in March 2024. | ||||
SG&A | Selling, general and administrative expenses | ||||
SID | Secure Information Destruction Services, a business unit that provides confidential customer material shredding services and recycling of shredded paper | ||||
SOFR | Secured Overnight Financing Rate - benchmark interest rate that replaced LIBOR | ||||
SOP | Sorted Office Paper | ||||
Term Facility | Aggregate amount of commitments made by any lender under the terms of the Credit Agreement | ||||
Term Loans | Advances made by any lender under the Term Facility | ||||
U.S. | United States of America | ||||
U.S. GAAP | U.S. Generally Accepted Accounting Principles |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 4 |
In millions, except per share data | |||||||||||
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Revenues | $ | 664.9 | $ | 684.3 | |||||||
Cost of revenues | 410.0 | 423.3 | |||||||||
Gross profit | 254.9 | 261.0 | |||||||||
Selling, general and administrative expenses | 216.0 | 216.0 | |||||||||
Divestiture losses, net (Note 4) | — | 5.0 | |||||||||
Income from operations | 38.9 | 40.0 | |||||||||
Interest expense, net | (18.4) | (20.4) | |||||||||
Other income, net | — | 0.2 | |||||||||
Income before income taxes | 20.5 | 19.8 | |||||||||
Income tax expense | (7.4) | (8.5) | |||||||||
Net income | 13.1 | 11.3 | |||||||||
Net income attributable to noncontrolling interests | — | (0.1) | |||||||||
Net income attributable to Stericycle, Inc. common shareholders | $ | 13.1 | $ | 11.2 | |||||||
Income per common share attributable to Stericycle, Inc. common shareholders: | |||||||||||
Basic | $ | 0.14 | $ | 0.12 | |||||||
Diluted | $ | 0.14 | $ | 0.12 | |||||||
Weighted average number of common shares outstanding: | |||||||||||
Basic | 92.6 | 92.3 | |||||||||
Diluted | 93.0 | 92.7 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 5 |
In millions | |||||||||||
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Net income | $ | 13.1 | $ | 11.3 | |||||||
Other comprehensive (loss) income: | |||||||||||
Currency translation adjustments | (11.5) | 7.9 | |||||||||
Total other comprehensive (loss) income | (11.5) | 7.9 | |||||||||
Comprehensive income | 1.6 | 19.2 | |||||||||
Less: comprehensive income (loss) attributable to noncontrolling interests | — | (2.2) | |||||||||
Comprehensive income attributable to Stericycle, Inc. common shareholders | $ | 1.6 | $ | 21.4 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 6 |
In millions, except per share data | |||||||||||
March 31, 2024 | December 31, 2023 | ||||||||||
ASSETS | |||||||||||
Current Assets: | |||||||||||
Cash and cash equivalents | $ | 31.0 | $ | 35.3 | |||||||
Accounts receivable, less allowance for doubtful accounts of $47.2 in 2024 and $44.7 in 2023 | 616.4 | 553.9 | |||||||||
Prepaid expenses | 33.6 | 31.6 | |||||||||
Other current assets | 47.8 | 50.7 | |||||||||
Total Current Assets | 728.8 | 671.5 | |||||||||
Property, plant and equipment, less accumulated depreciation of $680.2 in 2024 and $675.4 in 2023 | 722.6 | 708.3 | |||||||||
Operating lease right-of-use assets | 497.2 | 464.3 | |||||||||
Goodwill | 2,758.0 | 2,755.6 | |||||||||
Intangible assets, less accumulated amortization of $948.8 in 2024 and $925.8 in 2023 | 661.3 | 686.5 | |||||||||
Other assets | 67.8 | 66.4 | |||||||||
Total Assets | $ | 5,435.7 | $ | 5,352.6 | |||||||
LIABILITIES AND EQUITY | |||||||||||
Current Liabilities: | |||||||||||
Current portion of long-term debt | $ | 17.3 | $ | 19.6 | |||||||
Bank overdrafts | — | 1.0 | |||||||||
Accounts payable | 198.3 | 212.1 | |||||||||
Accrued liabilities | 210.9 | 259.5 | |||||||||
Operating lease liabilities | 109.1 | 105.4 | |||||||||
Deferred revenues | 70.1 | 72.6 | |||||||||
Other current liabilities | 49.2 | 47.8 | |||||||||
Total Current Liabilities | 654.9 | 718.0 | |||||||||
Long-term debt, net | 1,398.6 | 1,277.8 | |||||||||
Long-term operating lease liabilities | 407.8 | 378.9 | |||||||||
Deferred income taxes | 417.0 | 420.5 | |||||||||
Other liabilities | 34.3 | 34.5 | |||||||||
Total Liabilities | 2,912.6 | 2,829.7 | |||||||||
Commitments and contingencies (Note 9 - Commitments and Contingencies) | |||||||||||
EQUITY | |||||||||||
Common stock (par value $0.01 per share, 120.0 shares authorized, 92.8 and 92.6 issued and outstanding in 2024 and 2023, respectively) | 0.9 | 0.9 | |||||||||
Additional paid-in capital | 1,315.3 | 1,316.7 | |||||||||
Retained earnings | 1,402.5 | 1,389.4 | |||||||||
Accumulated other comprehensive loss | (196.0) | (184.5) | |||||||||
Total Stericycle, Inc.’s Equity | 2,522.7 | 2,522.5 | |||||||||
Noncontrolling interests | 0.4 | 0.4 | |||||||||
Total Equity | 2,523.1 | 2,522.9 | |||||||||
Total Liabilities and Equity | $ | 5,435.7 | $ | 5,352.6 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 7 |
In millions | |||||||||||
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
OPERATING ACTIVITIES: | |||||||||||
Net income | $ | 13.1 | $ | 11.3 | |||||||
Adjustments to reconcile net income to net cash from operating activities: | |||||||||||
Depreciation | 25.7 | 26.6 | |||||||||
Intangible amortization | 27.8 | 28.2 | |||||||||
Stock-based compensation expense | 2.7 | 6.9 | |||||||||
Deferred income taxes | (2.7) | 4.7 | |||||||||
Divestiture losses, net | — | 5.0 | |||||||||
Asset impairments, loss (gain) on disposal of property plant and equipment and other charges | 1.0 | (0.4) | |||||||||
Other, net | 1.3 | 0.5 | |||||||||
Changes in operating assets and liabilities: | |||||||||||
Accounts receivable | (64.4) | (4.4) | |||||||||
Prepaid expenses | (2.1) | (1.4) | |||||||||
Accounts payable | (12.5) | (6.3) | |||||||||
Accrued liabilities | (41.1) | (17.4) | |||||||||
Deferred revenues | (2.4) | 0.7 | |||||||||
Other assets and liabilities | (0.9) | (4.5) | |||||||||
Net cash from operating activities | (54.5) | 49.5 | |||||||||
INVESTING ACTIVITIES: | |||||||||||
Capital expenditures | (43.1) | (36.4) | |||||||||
(Payments) proceeds from (acquisition) divestiture of businesses, net | (14.0) | 0.9 | |||||||||
Other, net | 0.3 | 1.0 | |||||||||
Net cash from investing activities | (56.8) | (34.5) | |||||||||
FINANCING ACTIVITIES: | |||||||||||
Repayments of long-term debt and other obligations | (5.7) | (7.8) | |||||||||
Repayments of foreign bank debt | — | (0.1) | |||||||||
Repayments of senior notes | (600.0) | — | |||||||||
Proceeds from credit facility | 951.0 | 286.9 | |||||||||
Repayments of credit facility | (228.1) | (283.0) | |||||||||
Repayments of bank overdrafts, net | (0.9) | (0.5) | |||||||||
Payments of finance lease obligations | (0.6) | (0.7) | |||||||||
Proceeds from issuance of common stock, net of (payments of) taxes from withheld shares | (6.4) | (4.9) | |||||||||
Payments to noncontrolling interest | — | (1.5) | |||||||||
Net cash from financing activities | 109.3 | (11.6) | |||||||||
Effect of exchange rate changes on cash and cash equivalents | (2.3) | 0.6 | |||||||||
Net change in cash and cash equivalents | (4.3) | 4.0 | |||||||||
Cash and cash equivalents at beginning of period | 35.3 | 56.0 | |||||||||
Cash and cash equivalents at end of period | $ | 31.0 | $ | 60.0 | |||||||
SUPPLEMENTAL CASH FLOW INFORMATION: | |||||||||||
Interest paid, net of capitalized interest | $ | 35.1 | $ | 32.8 | |||||||
Income taxes paid, net | $ | 4.9 | $ | 0.4 | |||||||
Capital expenditures in Accounts payable | $ | 22.7 | $ | 18.8 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 8 |
In millions | |||||||||||||||||||||||||||||||||||||||||
Stericycle, Inc. Equity | |||||||||||||||||||||||||||||||||||||||||
Common Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Noncontrolling Interests | Total Equity | ||||||||||||||||||||||||||||||||||||
Shares | Amount | ||||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2023 | 92.6 | $ | 0.9 | $ | 1,316.7 | $ | 1,389.4 | $ | (184.5) | $ | 0.4 | $ | 2,522.9 | ||||||||||||||||||||||||||||
Net income | — | — | — | 13.1 | — | — | 13.1 | ||||||||||||||||||||||||||||||||||
Currency translation adjustment | — | — | — | — | (11.5) | — | (11.5) | ||||||||||||||||||||||||||||||||||
Issuance of common stock for incentive stock programs, net of (payments of) taxes from withheld shares | 0.2 | — | (4.1) | — | — | — | (4.1) | ||||||||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | 2.7 | — | — | — | 2.7 | ||||||||||||||||||||||||||||||||||
Balance as of March 31, 2024 | 92.8 | $ | 0.9 | $ | 1,315.3 | $ | 1,402.5 | $ | (196.0) | $ | 0.4 | $ | 2,523.1 | ||||||||||||||||||||||||||||
In millions | |||||||||||||||||||||||||||||||||||||||||
Stericycle, Inc. Equity | |||||||||||||||||||||||||||||||||||||||||
Common Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Noncontrolling Interests | Total Equity | ||||||||||||||||||||||||||||||||||||
Shares | Amount | ||||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2022 | 92.2 | $ | 0.9 | $ | 1,285.4 | $ | 1,410.8 | $ | (276.9) | $ | 4.3 | $ | 2,424.5 | ||||||||||||||||||||||||||||
Net income | — | — | — | 11.2 | — | 0.1 | 11.3 | ||||||||||||||||||||||||||||||||||
Currency translation adjustment | — | — | — | — | 10.2 | (2.3) | 7.9 | ||||||||||||||||||||||||||||||||||
Issuance of common stock for incentive stock programs, net of (payments of) taxes from withheld shares | 0.2 | — | (3.1) | — | — | — | (3.1) | ||||||||||||||||||||||||||||||||||
Stock-based compensation expense | — | — | 6.9 | — | — | — | 6.9 | ||||||||||||||||||||||||||||||||||
Changes in noncontrolling interest | — | — | — | — | — | (1.5) | (1.5) | ||||||||||||||||||||||||||||||||||
Balance as of March 31, 2023 | 92.4 | $ | 0.9 | $ | 1,289.2 | $ | 1,422.0 | $ | (266.7) | $ | 0.6 | $ | 2,446.0 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 9 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 10 |
In millions | |||||||||||
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Revenue by Service | |||||||||||
Regulated Waste and Compliance Services | $ | 447.8 | $ | 451.3 | |||||||
Secure Information Destruction Services | 217.1 | 233.0 | |||||||||
Total Revenues | $ | 664.9 | $ | 684.3 | |||||||
North America | |||||||||||
Regulated Waste and Compliance Services | $ | 376.5 | $ | 368.7 | |||||||
Secure Information Destruction Services | 192.7 | 204.7 | |||||||||
Total North America Segment | $ | 569.2 | $ | 573.4 | |||||||
International | |||||||||||
Regulated Waste and Compliance Services | $ | 71.3 | $ | 82.6 | |||||||
Secure Information Destruction Services | 24.4 | 28.3 | |||||||||
Total International Segment | $ | 95.7 | $ | 110.9 |
In millions | |||||||||||
March 31, 2024 | December 31, 2023 | ||||||||||
Other current assets | $ | 16.4 | $ | 16.1 | |||||||
Other assets | 46.9 | 46.1 | |||||||||
Total contract acquisition costs | $ | 63.3 | $ | 62.2 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 11 |
In millions | |||||||||||
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Beginning Balance | $ | 44.7 | $ | 53.3 | |||||||
Bad debt expense, net of recoveries | 5.9 | 2.2 | |||||||||
Write-offs | (3.9) | (5.8) | |||||||||
Other changes (1) | 0.5 | 0.5 | |||||||||
Ending Balance | $ | 47.2 | $ | 50.2 |
In millions | |||||
2024 | |||||
Cash | $ | 14.0 | |||
Promissory Notes | 1.8 | ||||
Total purchase price | $ | 15.8 |
In millions | |||||
2024 | |||||
Fixed assets | $ | 1.2 | |||
Intangibles (Customer Lists) | 6.1 | ||||
Goodwill | 8.2 | ||||
Other assets and liabilities, net | 0.3 | ||||
Total purchase price | $ | 15.8 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 12 |
In millions | |||||||||||
March 31, 2024 | December 31, 2023 | ||||||||||
$1.2 billion Credit Facility, due in 2026 | $ | 753.6 | $ | 31.0 | |||||||
$125 million Term Loan, due in 2026 | 125.0 | 125.0 | |||||||||
$600 million Senior Notes, due in 2024 (redeemed in March 2024) | — | 600.0 | |||||||||
$500 million Senior Notes, due in 2029 | 500.0 | 500.0 | |||||||||
Promissory notes and deferred consideration weighted average maturity of 2.5 years at 2024 and 2.6 years at 2023 | 29.0 | 32.9 | |||||||||
Obligations under finance leases | 14.8 | 16.3 | |||||||||
Total debt | 1,422.4 | 1,305.2 | |||||||||
Less: current portion of total debt | 17.3 | 19.6 | |||||||||
Less: unamortized debt issuance costs | 6.5 | 7.8 | |||||||||
Long-term portion of total debt | $ | 1,398.6 | $ | 1,277.8 |
Three Months Ended March 31, 2024 | Year Ended December 31, 2023 | ||||||||||
$1.2 billion Credit Facility, due in 2026 (variable rate) | 6.93 | % | 6.85 | % | |||||||
$125 million Term Loan, due in 2026 (variable rate) | 6.63 | % | 6.66 | % | |||||||
$600 million Senior Notes, due in 2024 (fixed rate) (redeemed in March 2024) | 5.38 | % | 5.38 | % | |||||||
$500 million Senior Notes, due in 2029 (fixed rate) | 3.88 | % | 3.88 | % | |||||||
Promissory notes and deferred consideration (fixed rate) | 3.43 | % | 3.54 | % | |||||||
In millions | |||||||||||
March 31, 2024 | December 31, 2023 | ||||||||||
Outstanding letters of credit under Credit Facility | $ | 55.2 | $ | 59.0 | |||||||
Unused portion of the Credit Facility | 391.2 | 1,110.0 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 13 |
In millions of shares | |||||||||||
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Weighted average common shares outstanding - basic | 92.6 | 92.3 | |||||||||
Incremental shares outstanding related to stock-based awards | 0.4 | 0.4 | |||||||||
Weighted average common shares outstanding - diluted | 93.0 | 92.7 |
In thousands of shares | |||||||||||
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Option awards | 477 | 815 | |||||||||
RSU awards | 102 | 1 |
In millions | |||||||||||
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Adjusted Income from Operations | |||||||||||
North America | $ | 149.1 | $ | 160.3 | |||||||
International | 12.4 | 10.3 | |||||||||
Other Costs | (71.0) | (85.9) | |||||||||
Total Adjusted Income from Operations | $ | 90.5 | $ | 84.7 | |||||||
2024 Q1 10-Q Report | Stericycle, Inc. ● | 14 |
In millions | |||||||||||
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Total Reportable Segment Adjusted Income from Operations | $ | 90.5 | $ | 84.7 | |||||||
Adjusting Items: | |||||||||||
ERP and System Modernization | (4.4) | (2.7) | |||||||||
Intangible Amortization | (27.8) | (28.2) | |||||||||
Operational Optimization | (5.6) | — | |||||||||
Portfolio Optimization | (1.6) | (5.6) | |||||||||
Litigation, Settlements and Regulatory Compliance | (12.2) | (8.2) | |||||||||
Income from operations | $ | 38.9 | $ | 40.0 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 15 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 16 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 17 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 18 |
In millions | |||||||||||
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Pre-tax items: | |||||||||||
Included in COR | |||||||||||
Operational Optimization | $ | 2.2 | $ | — | |||||||
Total included in COR | 2.2 | — | |||||||||
Included in SG&A | |||||||||||
ERP and System Modernization | 4.4 | 2.7 | |||||||||
Intangible Amortization | 27.8 | 28.2 | |||||||||
Operational Optimization | 3.4 | — | |||||||||
Portfolio Optimization | 1.6 | 0.6 | |||||||||
Litigation, Settlements and Regulatory Compliance | 12.2 | 8.2 | |||||||||
Total included in SG&A | 49.4 | 39.7 | |||||||||
Divestiture losses, net | — | 5.0 | |||||||||
Total included in Income from operations | $ | 51.6 | $ | 44.7 | |||||||
2024 Q1 10-Q Report | Stericycle, Inc. ● | 19 |
In millions | |||||||||||
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
North America | |||||||||||
Operating expenditures | $ | 2.7 | $ | 2.6 | |||||||
Capital expenditures | 1.8 | 2.9 | |||||||||
Total North America | $ | 4.5 | $ | 5.5 | |||||||
International | |||||||||||
Operating expenditures | $ | 1.7 | $ | 0.1 | |||||||
Capital expenditures | — | — | |||||||||
Total International | $ | 1.7 | $ | 0.1 | |||||||
Total operating expenditures | $ | 4.4 | $ | 2.7 | |||||||
Total capital expenditures | 1.8 | 2.9 | |||||||||
Total ERP and System Modernization | $ | 6.2 | $ | 5.6 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 20 |
Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||||||||||||||
In millions | Components of Change (%)(1) | ||||||||||||||||||||||||||||||||||||||||||||||
2024 | 2023 | Change ($) | Change (%) | Organic Growth(2) | Acquisition | Divestitures | Foreign Exchange(3) | ||||||||||||||||||||||||||||||||||||||||
Revenue by Service | |||||||||||||||||||||||||||||||||||||||||||||||
Regulated Waste and Compliance Services | $ | 447.8 | $ | 451.3 | $ | (3.5) | (0.8) | % | 2.1 | % | 0.2 | % | (3.5) | % | 0.5 | % | |||||||||||||||||||||||||||||||
Secure Information Destruction Services | 217.1 | 233.0 | (15.9) | (6.8) | % | (6.3) | % | 0.1 | % | (1.1) | % | 0.3 | % | ||||||||||||||||||||||||||||||||||
Total Revenues | $ | 664.9 | $ | 684.3 | $ | (19.4) | (2.8) | % | (0.8) | % | 0.1 | % | (2.7) | % | 0.4 | % | |||||||||||||||||||||||||||||||
North America | |||||||||||||||||||||||||||||||||||||||||||||||
Regulated Waste and Compliance Services | $ | 376.5 | $ | 368.7 | $ | 7.8 | 2.1 | % | 1.9 | % | 0.2 | % | — | % | — | % | |||||||||||||||||||||||||||||||
Secure Information Destruction Services | 192.7 | 204.7 | (12.0) | (5.9) | % | (6.0) | % | 0.1 | % | — | % | — | % | ||||||||||||||||||||||||||||||||||
Total North America Segment | $ | 569.2 | $ | 573.4 | $ | (4.2) | (0.7) | % | (0.9) | % | 0.2 | % | — | % | — | % | |||||||||||||||||||||||||||||||
International | |||||||||||||||||||||||||||||||||||||||||||||||
Regulated Waste and Compliance Services | $ | 71.3 | $ | 82.6 | $ | (11.3) | (13.7) | % | 3.0 | % | — | % | (18.5) | % | 2.3 | % | |||||||||||||||||||||||||||||||
Secure Information Destruction Services | 24.4 | 28.3 | (3.9) | (13.8) | % | (8.4) | % | — | % | (8.7) | % | 2.7 | % | ||||||||||||||||||||||||||||||||||
Total International Segment | $ | 95.7 | $ | 110.9 | $ | (15.2) | (13.7) | % | (0.2) | % | — | % | (16.0) | % | 2.4 | % |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 21 |
$ In millions | |||||||||||||||||||||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
2024 | 2023 | Change | |||||||||||||||||||||||||||||||||
$ | % Revenues | $ | % Revenues | $ | % | ||||||||||||||||||||||||||||||
Gross profit | 254.9 | 38.3 | % | 261.0 | 38.1 | % | (6.1) | (2.3) | % |
$ In millions | |||||||||||||||||||||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
2024 | 2023 | Change | |||||||||||||||||||||||||||||||||
$ | % Revenues | $ | % Revenues | $ | % | ||||||||||||||||||||||||||||||
SG&A | 216.0 | 32.5 | % | 216.0 | 31.6 | % | — | — | % |
$ In millions | |||||||||||||||||||||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
2024 | 2023 | Change | |||||||||||||||||||||||||||||||||
$ | % Revenues | $ | % Revenues | $ | % | ||||||||||||||||||||||||||||||
Divestiture losses, net | — | — | % | 5.0 | 0.7 | % | (5.0) | (100.0) | % |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 22 |
In millions | |||||||||||||||||||||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
2024 | 2023 | Change 2024 versus 2023 | |||||||||||||||||||||||||||||||||
$ | % Segment Revenues | $ | % Segment Revenues | $ | % | ||||||||||||||||||||||||||||||
Adjusted Income from Operations | |||||||||||||||||||||||||||||||||||
North America | 149.1 | 26.2 | % | 160.3 | 28.0 | % | (11.2) | (7.0) | % | ||||||||||||||||||||||||||
International | 12.4 | 13.0 | % | 10.3 | 9.3 | % | 2.1 | 20.4 | % | ||||||||||||||||||||||||||
Other Costs | (71.0) | nm | (85.9) | nm | 14.9 | 17.3 | % | ||||||||||||||||||||||||||||
Total | 90.5 | 13.6 | % | 84.7 | 12.4 | % | 5.8 | 6.8 | % | ||||||||||||||||||||||||||
Reconciliation to Income from operations | |||||||||||||||||||||||||||||||||||
Adjusted Income from Operations | 90.5 | 84.7 | |||||||||||||||||||||||||||||||||
Adjusting Items Total (1) | (51.6) | (44.7) | |||||||||||||||||||||||||||||||||
Income from operations | 38.9 | 40.0 |
$ In millions | |||||||||||||||||||||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
2024 | 2023 | Change | |||||||||||||||||||||||||||||||||
$ | % Revenues | $ | % Revenues | $ | % | ||||||||||||||||||||||||||||||
Interest expense, net | 18.4 | 2.8 | % | 20.4 | 3.0 | % | (2.0) | (9.8) | % |
$ In millions | |||||||||||||||||||||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
2024 | 2023 | Change | |||||||||||||||||||||||||||||||||
$ | % Revenues | $ | % Revenues | $ | % | ||||||||||||||||||||||||||||||
Other income, net | — | — | % | 0.2 | — | % | (0.2) | (100.0) | % |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 23 |
$ In millions | |||||||||||||||||||||||||||||||||||
Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||
2024 | 2023 | Change | |||||||||||||||||||||||||||||||||
$ | Effective Rate | $ | Effective Rate | $ | % | ||||||||||||||||||||||||||||||
Income tax expense | 7.4 | 36.1 | % | 8.5 | 42.9 | % | (1.1) | (12.9) | % |
In millions | |||||||||||
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Net cash from operating activities | $ | (54.5) | $ | 49.5 | |||||||
Net cash from investing activities | (56.8) | (34.5) | |||||||||
Net cash from financing activities | 109.3 | (11.6) | |||||||||
Effect of exchange rate changes on cash and cash equivalents | (2.3) | 0.6 | |||||||||
Net change in cash and cash equivalents | $ | (4.3) | $ | 4.0 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 24 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 25 |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 26 |
PART II – OTHER INFORMATION |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 27 |
Exhibit Index | Description | |||||||
3.1 | ||||||||
3.2 | ||||||||
3.3 | ||||||||
3.4 | ||||||||
3.5 | ||||||||
3.6 | ||||||||
3.7 | ||||||||
3.8 | ||||||||
3.9 | ||||||||
3.10 | ||||||||
10.1 | ||||||||
10.2 | ||||||||
10.3 | ||||||||
31.1 | ||||||||
31.2 | ||||||||
32 | ||||||||
101 | The following information from our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in Inline XBRL: (i) Condensed Consolidated Statements of Income; (ii) Condensed Consolidated Statements of Comprehensive Income; (iii) Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Cash Flows; (v) Condensed Consolidated Statements of Changes in Equity; (vi) Notes to Condensed Consolidated Financial Statements, and (vii) the information under Part II, Item 5, “Other Information” | |||||||
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 28 |
STERICYCLE, INC. | |||||
(Registrant) | |||||
By: /s/ JANET H. ZELENKA | |||||
Janet H. Zelenka | |||||
Executive Vice President, Chief Financial Officer & Chief Information Officer |
2024 Q1 10-Q Report | Stericycle, Inc. ● | 29 |
/s/ CINDY J. MILLER | ||||||||
Cindy J. Miller | ||||||||
Chief Executive Officer | ||||||||
Stericycle, Inc. |
/s/ JANET H. ZELENKA | ||||||||
Janet H. Zelenka | ||||||||
Executive Vice President, Chief Financial Officer & Chief Information Officer | ||||||||
Stericycle, Inc. |
/s/ CINDY J. MILLER | ||||||||
Cindy J. Miller | ||||||||
Chief Executive Officer | ||||||||
Stericycle, Inc. |
/s/ JANET H. ZELENKA | ||||||||
Janet H. Zelenka | ||||||||
Executive Vice President, Chief Financial Officer & Chief Information Officer | ||||||||
Stericycle, Inc. |